Background Infections are associated with biological therapies in psoriasis. Objectives To summarize the incidence of infections in patients with moderate-tosevere psoriasis treated with ixekizumab, an anti-interleukin-17A monoclonal antibody. Methods Infections are summarized from an integrated database of seven controlled and uncontrolled ixekizumab psoriasis trials. Data are presented from placebo-controlled induction (weeks 0-12; UNCOVER-1, UNCOVER-2 and UNCOVER-3) and maintenance periods (weeks 12-60; UNCOVER-1 and UNCOVER-2), and all patients exposed to ixekizumab pooled from all seven trials. Comparisons with etanercept were made during the induction period of two trials (UNCOVER-2 and UNCOVER-3). Incidence and exposure-adjusted incidence rates (IRs) per 100 patient-years (PYs) are reported. Results Overall, 4209 patients were treated with ixekizumab (6480 PY). During induction (weeks 0-12), overall infection rates were higher in patients treated with ixekizumab (27%) vs. placebo (23%, P < 0Á05); however, specific infection rates were comparable overall across treatment groups. IRs of infections did not increase with longer-term exposure. For all patients treated with ixekizumab (all seven trials), the incidence of serious infections was low (2%, IR 1Á3). Candida infections, including eight cases of oesophageal candidiasis, were adequately managed with antifungal therapy, were noninvasive and did not lead to discontinuation. Conclusions Overall, infections occurred in a higher percentage of patients treated with ixekizumab vs. placebo during the first 12 weeks of treatment; however, specific infection rates were comparable overall across treatment groups. Incidences of serious infections were low and similar across treatment groups.
• The overall safety of ixekizumab has been previously reported; this paper endeavours to provide more specific information about infections.
What does this study add?
• We report the incidence of specific treatment-emergent infections reported in a database of > 4000 patients with moderate-to-severe psoriasis treated with ixekizumab.
• This study provides detailed accounts of infection-related adverse events categorized by special topics, including tuberculosis, Candida infections, staphylococcal infections, herpes zoster, viral hepatitis and infections preceded/accompanied by neutropenia.
• We performed sensitivity analyses of infection rates over time for all patients treated with ixekizumab (12-week interval analyses up to 108 weeks and times to occurrence of infection events).
Biological therapies have improved the clinical management of moderate-to-severe psoriasis ('psoriasis') owing to a favourable benefit-risk balance without cumulative organ-specific toxicity. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] However, biological therapies have been associated with an increased risk of infections in clinical trials, the majority of which are nonserious upper respiratory tract infections. [1] [2] [3] [4] [5] 11, 12 Serious infections have also been reported, but with a low incidence. [1] [2] [3] [4] [5] 11, 12 An increased risk of developing active tuberculosis (TB) has been observed with some tumour necrosis factor (TNF)-a blockers. 13 Opportunistic fungal infections (e.g. serious forms of histoplasmosis, coccidioidomycosis or blastomycosis) have also been reported with anti-TNFa medications.
14-17
More recently, interleukin (IL)-17A antagonists have demonstrated substantial clinical effect in patients with psoriasis. 11, 12, 18 IL-17 plays an important role in host mucocutaneous defence against extracellular pathogens. [19] [20] [21] Included among these pathogens are fungi, particularly the yeast Candida albicans. [20] [21] [22] [23] [24] Individuals with deficiencies in T helper 17 cells (hyper-IgE syndrome or Job syndrome), IL-17RA or IL-17F exhibit increased susceptibility to mucocutaneous candidiasis and staphylococcal infections. 22, 23 Here we report infections from an integrated database of seven psoriasis clinical trials comprising 4209 patients with 6480 patient-years (PYs) of total ixekizumab exposure. 25 Patients and methods
Study design
Data from seven ixekizumab clinical trials are presented in this report (Table 1 , Figs S1, S2; see Supporting Information). 25 Main data sources were UNCOVER-1, UNCOVER-2 and UNCOVER-3, which are randomized, double-blind, placebocontrolled phase III psoriasis trials with a 12-week placebocontrolled induction dosing period. 11, 18, 25 UNCOVER-2 and UNCOVER-3 had an active comparator (etanercept, 50 mg twice weekly) group during the induction period. 11, 25 UNCOVER-1 and UNCOVER-2 had a placebo-controlled 48-week maintenance dosing period (weeks 12-60). 18, 25 These UNCOVER trials have a long-term extension period to week 264. Trials were registered on clinicaltrials.gov [NCT01474512 (UNCOVER-1); NCT01597245 (UNCOVER-2); NCT01646177 (UNCOVER-3); NCT01777191 (UNCOVER-A); NCT01624233 (UNCOVER-J); NCT01107457 (I1F-MC-RHAJ)].
Patients
Patients (≥ 18 years) with moderate-to-severe psoriasis [≥ 10% body surface area involvement, static Physician's Global Assessment (sPGA) ≥ 3, Psoriasis Area and Severity Index (PASI) ≥ 12 at baseline] who were candidates for systemic therapy and/or phototherapy met prespecified inclusion and exclusion criteria for enrolment in all seven studies. Infectionspecific criteria are reported in Table S1 (see Supporting Information). Protocols received ethical review board approval and patients gave written informed consent.
In accordance with the protocol, screening was mandated at baseline and, in the phase II and III trials, yearly thereafter for evidence of TB using either a tuberculin skin test (TST) or QuantiFERON â -TB Gold In-tube test (QFT-GIT). In phase III studies, patients with a positive TST (i.e. induration ≥ 5 mm) or QFT-GIT at screening, but no other evidence of active TB, were eligible for enrolment 4 weeks after starting latent TB infection therapy. Patients with an active TB infection on a chest radiograph were excluded at screening. Patients with a positive TB test at week 52, or yearly thereafter, were discontinued. Patients with hepatitis C were excluded from enrolment (Table S1 ; see Supporting Information). In phase III studies, patients who were positive for hepatitis B virus (HBV) core antibody, negative for surface antigen and were negative for HBV DNA could be enrolled with monitoring (Table S1 ; see Supporting Information).
Safety evaluations
There were four integrated analysis sets ( Table 1 ). The induction period (weeks 0-12) is represented by the primary placebo-controlled (comparisons with placebo; UNCOVER-1, UNCOVER-2 and UNCOVER-3) and placebo-and active-controlled (comparisons with etanercept; UNCOVER-2 and UNCOVER-3) analysis sets. The maintenance period (weeks 12-60) is represented by the psoriasis maintenance analysis set (this set comprises indution period ixekizumab responders who were rerandomized to ixekizumab or placebo in the maintenance period; UNCOVER-1 and UNCOVER-2). The allixekizumab-psoriasis (AP) analysis set comprises data from all patients treated with ixekizumab from seven clinical trials.
The safety population comprised all patients who received at least one dose of the study treatment. At each visit, patients volunteered whether they experienced an adverse event (AE), which was evaluated, monitored and reported by the investigator. Serious AEs included death or an event that may be lifethreatening, required initial or prolonged hospitalization, led to disability or congenital anomaly/birth defect, or was otherwise considered significant by the investigator. In the phase III studies, investigators were instructed to complete a specific case report form for infection events. Infection severity was judged by the investigator and rated as mild, moderate or severe. Infections were not adjudicated. The AEs analysed were those coded to Medical Dictionary for Regulatory Activities preferred terms and classified by Infections and Infestations System Organ Class. A treatment-emergent AE (TEAE) was an event first occurring or worsening in severity after baseline and on, or prior to, the last day of the treatment period. Exposure-adjusted incidence rates (IRs) for TEAEs represent the number of unique patients with a specific event per 100 PY of exposure. Time during the treatment period was considered to be the entire exposure time. If an event occurred multiple times for a patient, the event was counted once. Neutropenia was defined using Common Terminology Criteria for Adverse Events grade 2 or greater (absolute neutrophil count < 1Á5 9 10 9 L À1 ). Infection events with an onset date ≤ 14 days before or after the grade 2 neutrophil count collection date were considered to be infections preceded or accompanied by neutropenia. Staphylococcal infections and candidiasis were based on clinical impression, and in some cases, microbiological confirmation. Statistical comparisons were made between treatment groups within specific periods; there were no comparisons made between groups across periods. Treatment comparisons for frequencies were analysed using the Cochran-MantelHaenszel test stratified by study. 26 A Poisson regression model (treatment as explanatory variable) was used to compare exposure-adjusted IRs. 27 For supplementary analyses, 12-week interval analyses (weeks 0-108) were conducted, and times to occurrence of infection events for all patients treated with a The integrated databases for this report were also utilized in a report to summarize the overall safety profile of ixekizumab. These data have been previously reported by Strober et al. 25 The cut-off date for data presented in this report was 9 April 2015.
ixekizumab were summarized using Kaplan-Meier survival curves and life table hazard rate curves. Statistical tests with two-sided P-values < 0Á05 were considered statistically significant. For IRs, 95% confidence intervals (CIs) were reported. Subgroup analyses were performed; results from baseline weight (< 100, ≥ 80 kg to < 100 kg, ≥ 100 kg) and previous biological therapy use (never used vs. ever used) are presented in this report. To test treatment-by-subgroup interactions, a logistic regression with study, treatment, subgroup and treatment-by-subgroup interaction was used.
Results

Patients and exposure
From all seven trials, 4209 patients received at least one ixekizumab dose with 6480 PY of total exposure (median 507 days; maximum 1794 days) ( Table 1 and Table S2 ; see Supporting Information). 25 As of the data cut-off date, 3298
patients were treated for > 1 year, while 1166 patients were treated for > 2 years (Table S2 ; see Supporting Information). Baseline demographics and patient characteristics were generally similar between treatment groups during the induction and maintenance periods ( Table 2) .
Overall infections
Induction period: comparisons between ixekizumab and placebo or etanercept
During the 12-week induction period, 27% of patients from the pooled ixekizumab group had at least one infection compared with 23% from the placebo group, although IRs were not significantly different ( Table 3) . Rates of specific infections were comparable overall across induction period treatment groups and were most often mild or moderate in severity and not serious ( (Table 3 , Fig. 1 and Table S4 ; see Supporting Information). Cellulitis (n = 3), appendicitis (n = 2) and erysipelas (n = 2) were reported from more than one patient treated with ixekizumab; two cellulitis events and two appendicitis events led to discontinuation (Table S3 ; see Supporting Information). Overall, IRs of infections that led to discontinuation were low and similar across treatment groups during this period (Table 3 and Table S3 ; see Supporting Information).
Maintenance period and analyses of ixekizumab exposure for all patients with psoriasis: longer-term evaluation of treatment-emergent infections
The most commonly reported events for patients treated with ixekizumab during the maintenance period were similar to events reported from the pooled ixekizumab group during the induction period (Tables S3-S5; see Supporting Information) and resolved in generally the same time frame. Table S6 ( IRs of serious infections were similar across treatment groups during the maintenance period (weeks 12-60; Table 3 ). No specific serious infection occurred in more than one patient during the maintenance period 25 and none led to discontinuation. Over all seven trials, three patients treated with ixekizumab (0Á1%) had a recurrence of serious infections that they had previously experienced (i.e. pneumonia, erysipelas, sepsis). Additionally, 1% [IR 0Á7 (95% CI 0Á51-0Á91)] of all patients treated with ixekizumab (all seven trials) discontinued owing to an infection (Table 3) . Table S6 ( 
Special topics
Tuberculosis
There were 102 patients enrolled across all seven trials with a history of either treated possible latent TB (n = 4) or a positive TST or QFT-GIT (n = 98) at screening. All 102 patients started and were required to complete preventive therapy before or during the study; none developed active TB. There were 36 patients treated with ixekizumab (0Á9%) whose TST or QFT-GIT was converted to positive during the study; all were discontinued. TB findings may be impacted by the sensitivity and inherent variability of the QFT-GIT. There have been no active TB cases reported in ixekizumab clinical trials. 25 
Candida infections
During the induction period, IRs (95% CIs) of Candida infections overall were numerically higher in the pooled ixekizumab group [4Á3 (95% CI 2Á9-6Á5)] compared with 
Male sex 
Á7
Ethnicity Asian
Black or African American
Á5
Other or multiple
North America 
Á2
Central/South
Prior systemic therapy Never 
Á6
Biological and nonbiological
Á2
Prior biological therapy Never 
One therapy
Three or more therapies
Duration of psoriasis symptoms (years) 
Discontinuations from study
AE, adverse event; AP, all psoriasis ixekizumab exposure; IXE, ixekizumab; PBO, placebo; PsM, psoriasis maintenance; PPC, primary placebo-controlled; Q4W, every 4 weeks; Q12W, every 12 weeks; Q2W, every 2 weeks; SIE, serious infection event; TEAE, treatment-emergent adverse event. Serious infections were defined as any infectious event resulting in death or that may be life-threatening, requiring initial or prolonged hospitalization, leading to disability or congenital anomaly/birth defect or otherwise considered to be significant by the investigator. Total patient-years = total exposure time in years within the treatment period. Exposure-adjusted IRs for TEAEs/SIEs represent the number of unique patients with a particular event per 100 patient-years of exposure. Time during the treatment period was considered entire exposure time. a n (%, IR) for infection-related TEAEs and SIEs have been previously reported by Gordon et al.
placebo [2Á2 (95% CI 0Á8-5Á9)] 18 (Table 4) ; the etanercept group IR was 3Á0 (95% CI 1Á2-7Á1) 25 (Table 5 ). Oral candidiasis was among the most commonly reported Candida infections for patients treated with ixekizumab. 25 Proportionally, oral candidiasis was statistically more frequent in the ixekizumab Q2W group (0Á8%) than in the placebo group (0%, P = 0Á016) and was also significantly higher in the ixekizumab Q2W group (0Á8%) than in the ixekizumab Q4W group (0Á2%, P = 0Á035), signifying a dose effect during this period; however, IRs were not significantly different. IRs of Candida infections overall and oral candidiasis were 2Á5 (95% CI 2Á2-3Á0) and 1Á2 (95% CI 1Á0-1Á5), 25 respectively (all seven trials) ( Table 6 , Fig. 2a, b) . For patients treated with ixekizumab, the median duration for Candida infections overall was 4 weeks (all seven trials). Over 80% of patients with Candida-related events had resolved or resolving infection(s) by the data cut-off per investigator judgement. 25 No reported
Candida infections led to treatment discontinuation. Eight patients across all seven trials (IR 0Á1) were reported to have oesophageal candidiasis while receiving ixekizumab or (in one patient) shortly thereafter following rerandomization to placebo during the maintenance period (Table 6) . 25 Five patients had potential risk factors (≥ 65 years of age, obesity and type 2 diabetes mellitus) for the event reported at baseline. Four patients had oesophageal candidiasis confirmed by oesophagogastroduodenoscopy (EGD). Two reported oesophageal candidiasis events were considered serious from two patients in the ixekizumab Q4W group during long-term extension treatment. One patient with preexisting type 2 diabetes mellitus was hospitalized for oesophageal candidiasis after 411 days of ixekizumab treatment. The patient was treated with oral antifungal agents, recovered after 1 week and continued ixekizumab treatment. Another patient without reported baseline risk factors was hospitalized for oesophageal candidiasis after being treated with ixekizumab for 477 days. The patient was discharged after 2 days and continued treatment for the active infection while being administered ixekizumab. The patient recovered after 36 days. All oesophageal candidiasis events were considered recovered. There were no reports of invasive candidiasis (involving candidaemia or deep organ involvement) or any other invasive fungal infections, such as disseminated histoplasmosis or invasive pulmonary aspergillosis.
Staphylococcal infections
IRs for staphylococcal infections were similar across treatment groups during both the induction and maintenance periods and remained stable with longer-term ixekizumab exposure (Tables 4-6 ). In addition, cellulitis and erysipelas were reported in patients treated with ixekizumab across all seven trials for which the causative pathogen was not confirmed. Over 85% of patients with reported cellulitis had infections considered by the investigator to be resolved by the data cutoff; approximately 84% of these patients received antibiotic treatment within 14 days of diagnosis (most were treated within the first few days).
Herpes zoster
There were no reports of herpes zoster infections in patients treated with ixekizumab during the induction period (Tables 4-5), while two patients treated with ixekizumab were reported to have herpes zoster infections during the Fig 1. Serious infections. Exposure-adjusted incidence rates per 100 PY. The symbol represents the exposure-adjusted incidence rate and the bars signify the 95% confidence intervals (CIs). During the placebo-controlled period the incidence rates for placebo (PBO), ixekizumab (IXE) every 4 weeks (Q4W) and IXE every 2 weeks (Q2W) are from the primary placebo-controlled (PPC) analysis set and the incidence rate for etanercept (ETN) is taken from the placebo-and active-controlled (PAC) analysis set. 25 The 12-60 week maintenance data and all IXE data have been previously presented. 25 Ps, psoriasis; Q12W, every 12 weeks; LTE, long-term extension; n, number of unique patients with a specific event; RCT, randomized controlled trial; WD, withdrawal.
maintenance period ( Table 6 ). The IR for herpes zoster infections in patients treated with ixekizumab across all seven trials was 0Á6; none of the events were serious and none led to treatment discontinuation.
Viral hepatitis
Viral hepatitis was not reported in any treatment group during the induction or maintenance periods (Tables 4-6 ).
Across all seven trials, one patient treated with ixekizumab was reported to have a nonserious new hepatitis C infection (Table 6 ). This patient discontinued treatment and was lost to follow-up.
Infections preceded/accompanied by neutropenia
IRs of infections associated with neutropenia were low and similar across treatment groups during both the induction and Oral herpes, n (IR)
Patients with at least one TEAE -infections preceded/ accompanied by neutropenia, n [IR (95% CI)]
[1Á1 (0Á3-4Á4)] 4 [1Á5 (0Á6-4Á0)] [0Á7 (0Á2-3Á0)] 6 [1Á1 (0Á5-2Á5)]
Urinary tract infection, n (IR) (Tables 4-6 ). Overall, across all seven trials, 24 patients treated with ixekizumab (0Á6%) had infections associated with neutropenia grade 2 or higher (grade 2, n = 22; grade 3, n = 2), with the most common being nasopharyngitis (n = 11), upper respiratory tract infection (n = 4), rhinitis (n = 2) and urinary tract infection (n = 2) ( Table 6) . No patient experienced a serious infection associated with neutropenia. 
Patients with at least one TEAE -herpes zoster,
Patients with at least one TEAE -herpes simplex, 
CI, confidence interval; ETN, etanercept; IXE, ixekizumab; Q4W, every 4 weeks; Q2W, every 2 weeks; PBO, placebo. Total patient-years (PYs) = total exposure time in years within the treatment period. Exposure-adjusted IRs for TEAEs represent the number of unique patients with a particular event per 100 PYs of exposure. Neutropenia was defined as Common Terminology Criteria for Adverse Events grade 2 or greater (absolute neutrophil count < 1Á5 9 10 9 L À1 ). a Denominator adjusted owing to sex-specific event for female patients: PY = 23Á7 (placebo), PY = 53Á8 (ETN); PY = 53Á2 (IXE 80 mg Q4W), PY = 59Á9 (IXE 80 mg Q2W); PY = 113Á1 (pooled IXE). Candida infections have been previously reported by Strober et al. Denominator adjusted owing to sex-specific event for female patients:
Discussion
Infections remain an important topic of concern for biologics. The overall safety of ixekizumab has been reported elsewhere, 25 whereas this report endeavours to provide a detailed profile of treatment-emergent infections reported with ixekizumab treatment in a large clinical development psoriasis programme. While infection rates, predominantly driven by nonserious upper respiratory tract infections, were higher in patients treated with ixekizumab compared with patients treated with placebo or etanercept during the first 12 weeks, the profile of commonly reported events was comparable across treatment groups overall. An exception was oral candidiasis, for which the incidence in patients treated with ixekizumab Q2W was significantly higher than those treated with ixekizumab Q4W, signifying a dose effect. The majority of infections were mild or moderate in severity and did not lead to treatment discontinuation. Infection rates overall did not increase with longer-term ixekizumab exposure, which is supported by the time-interval, Kaplan-Meier and hazard rate curve analyses ( Fig. S3-S5 ; see Supporting Information). When hazard rates are nonconstant over long time intervals (e.g. overall infections, Fig. S5 ; see Supporting Information), the overall exposure-adjusted IR by itself should be interpreted with caution and supported by other evidence. The increased incidence of oral candidiasis in ixekizumab groups, both during the initial 12-week treatment and over time, is consistent with the mechanism of action of ixekizumab as IL-17A is known to be involved in mucosal defence against this organism and others, including Staphylococcus aureus. [20] [21] [22] [23] [24] Similar to published literature on other IL-17A
antagonists, candidiasis cases, including the few oesophageal candidiasis cases (n = 8, 0Á2%), were generally manageable with standard antifungal treatments and did not lead to treatment discontinuation. 25 Notably, the prevalence of EGD-confirmed oesophageal candidiasis from three retrospective investigations of immunocompetent healthy individuals ranged from 0Á32% to 1Á17%. [28] [29] [30] Although this range provides context for the prevalence reported here, investigations in large cohorts of immunocompetent white patients and in patients with psoriasis are lacking. Furthermore, no invasive candidiasis or other opportunistic fungal infections were reported for patients treated with ixekizumab, which is relevant given During the placebo-controlled period the incidence rates for placebo (PBO), ixekizumab (IXE) every 4 weeks (Q4W) and IXE every 2 weeks (Q2W) are from the primary placebo-controlled (PPC) analysis set and the incidence rate for etanercept (ETN) is taken from the placebo-and active-controlled (PAC) analysis set. 25 The 12-60 week maintenance data and all IXE data have been previously presented. 25 Ps, psoriasis; DB, double-blind; Q12W, every 12 weeks; LTE, long-term extension; n, number of unique patients with a specific event; RCT, randomized controlled trial; WD, withdrawal.*P < 0Á05 (Q2W vs. Q4W).
concerns over serious opportunistic infections associated with some antipsoriatic treatments. 17, 31 Serious infection rates were low and balanced across treatment groups and periods. The most frequently reported serious infection in patients treated with ixekizumab was cellulitis (0Á4%; all seven trials). 25 This was not unexpected as S. pyogenes and S. aureus are pathogens commonly associated with cellulitis, and patients with deficient IL-17 immunity have shown an increased risk of cutaneous infection owing to S. aureus.
22,23
Importantly, there was no apparent increased risk of infections with neutropenia. Rates of herpes zoster were low in patients treated with ixekizumab and were consistent with background rates expected for patients with psoriasis. 32 There were no active TB cases; 25 however, this could be related to the screening and treatment of patients with possible latent TB. Although there were patients who converted their TST or QFT-GIT during yearly evaluation, evidence suggests that in individuals with a low risk of Mycobacterium tuberculosis infection positive test results are likely to be falsely positive. 33, 34 A majority of patients in these clinical trials were from countries with overall low TB rates. No active TB was reported upon follow-up in any patient who converted his/ her TST or QFT-GIT to positive during yearly evaluation.
Despite the absence of a demonstrable TB risk with ixekizumab, and lack of evidence for IL-17A involvement in TB pathogenesis, evaluating patients for TB is recommended along with appropriate treatment when TB or an increased TB risk is suspected before instituting ixekizumab. Subsequent monitoring for TB signs or symptoms during treatment will be prudent until longer-term safety data in real-world settings confirms the lack of a TB signal. These results, along with recently published data on the clinical efficacy and overall safety profile of ixekizumab, 11, 18, 25 support a positive benefit-risk profile for ixekizumab, although the analyses used have important limitations. Longterm comparisons of treated and untreated patients were limited as few patients initially randomized to placebo remained on placebo for > 12 weeks. Comparison with etanercept was limited to 12 weeks. Longer-term serious infection rates were consistent with the rates observed in large epidemiological databases, 35, 36 but it remains possible that clinical trial populations do not fully represent the general population with psoriasis. Whereas a significantly greater percentage of patients had infections overall, there were no significant differences by indirect comparison (i.e. CIs) and the individual infection rates were overall comparable, leaving uncertainty regarding causality. However, for Candida infections, and particularly oral candidiasis, there is biological plausibility for a causal relationship. Ixekizumab use within a clinical trial setting, in which patients may present with fewer comorbidities than in realworld settings, may underestimate the risks of infection. Of the seven studies, six had at least one open-label period(s) or treatment groups; therefore, information bias could have been introduced during these unblinded periods. Greater exposure over time will further define the safety profile of ixekizumab, and ongoing efforts to characterize this profile in greater detail include extensions of the phase III clinical trials to 5 years and involvement in existing registries.
In conclusion, the profile of treatment-emergent infections in > 4000 patients with psoriasis who were administered ixekizumab (6480 PY) for up to 4 years from seven clinical trials was consistent with expectations for an IL-17A antagonist.
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Fig S1. Details of psoriasis studies comprising integrated analysis sets. Fig S2. Patient disposition during the induction period of UNCOVER-1, UNCOVER-2 and UNCOVER-3 and the maintenance period for UNCOVER-1 and UNCOVER-2. Fig S3. Overall infection treatment-emergent adverse events (TEAEs). Exposure-adjusted incidence rates per 100 patientyears are shown for all patients treated with ixekizumab by 12-week intervals and over the 108 weeks of data collected up to the data cut-off date. Fig S4. Overall infection treatment-emergent adverse events (TEAEs). Kaplan-Meier plot of time from first dosing to first occurrence of infection-related TEAE occurring in at least 1% of patients in the total ixekizumab group from all seven trials (AP analysis set). Fig S5. Overall infection treatment-emergent adverse events (TEAEs). Hazard rate plot of time from first dosing to first occurrence of infection-related TEAE occurring in at least 1% of patients in the total ixekizumab group from all seven trials (AP analysis set). Fig S6. Serious infections. Exposure-adjusted incidence rates per 100 patient-years are shown for all patients treated with ixekizumab by 12-week intervals and over the 108 weeks for data collected up to the data cut-off. Fig S7. Serious infection events. Kaplan-Meier plot of time from first dosing to first occurrence of serious infection events occurring in at least 1% of patients in the total ixekizumab group from all seven trials (AP analysis set). Fig S8. Serious infection events. Hazard rate plot of time from first dosing to first occurrence of serious infection events occurring in at least 1% of patients in the total ixekizumab group from all seven trials (AP analysis set). Data is captured over 12-week intervals from Weeks 0-108.
